Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
Thoracic Cancer ( IF 2.9 ) Pub Date : 2021-09-12 , DOI: 10.1111/1759-7714.14141
Chen Zhang ₁ , Honggang Cao _{1,

2} , Yanan Cui ₁ , Shidai Jin ₁ , Wen Gao ₁ , Chenjun Huang ₃ , Renhua Guo ₁

Affiliation

Acquired resistance development is a major challenge in the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR–TKI) treatment of non–small cell lung cancer (NSCLC). Here, we investigated the potential effects of the concurrent use of anlotinib and EGFR-TKI to overcome acquired resistance.

中文翻译：

同时使用安罗替尼可克服晚期 EGFR 突变非小细胞肺癌患者对 EGFR-TKI 的获得性耐药

获得性耐药性发展是表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI) 治疗非小细胞肺癌 (NSCLC) 的主要挑战。在这里，我们研究了同时使用安罗替尼和 EGFR-TKI 克服获得性耐药的潜在影响。

更新日期：2021-10-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>